Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis - Phase II Single Center Study

NCT00824980 is registered in ClinicalTrials.gov with Immune Technologies & Medicine GmbH as lead sponsor.

NCT NCT00824980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00824980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis - Phase II Single Center Study
Lead sponsor
Immune Technologies & Medicine GmbH
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2009
Completion date
September 30, 2009
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis